Voyager Therapeutics, Inc.
VYGR · XNASCIK 1640266fmd_12B25K46MQ2B3ZPNGZ61HGCBAMManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 52 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 14 | 10 | 8 | 104 | 171 | 37 | 41 | 250 | 80 | 40 |
| Rental revenue | – | – | – | – | – | 1 | 1 | – | 1 | – |
| Research and development | 42 | 62 | 65 | 120 | 109 | 74 | 61 | 92 | 127 | 135 |
| Total operating expenses | 56 | 82 | 99 | 156 | 144 | 111 | 92 | 128 | 163 | 172 |
| Operating income | (41) | (72) | (91) | (52) | 27 | (74) | (51) | 122 | (83) | (132) |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 1 | 1 | 3 | 8 | 9 | 2 | 4 | 12 | 19 | 12 |
| Income before taxes | (40) | (71) | (88) | (44) | 37 | (71) | (46) | 134 | (64) | (120) |
| Income tax expense | 0 | – | (0) | – | – | – | 0 | 1 | 1 | 0 |
| Net income from continuing operations | (40) | – | (88) | – | – | – | (46) | 132 | (65) | (120) |
| Net income | (40) | (71) | (88) | (44) | 37 | (71) | (46) | 132 | (65) | (120) |
| Net income to common shareholders | (40) | (71) | (88) | (44) | 37 | (71) | (46) | 132 | (65) | (120) |